Business Context and Reporting Period
This Form 8-K is a current report filed by Bioaffinity Technologies, Inc. (Nasdaq: BIAF) on September 8, 2026. The filing addresses a critical corporate governance event regarding the company's continued listing status on The Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or debt levels. However, it discloses the following market data as of September 8, 2026:
- Outstanding Common Stock: 1,166,625 shares
- Aggregate Market Value: Approximately $10.4 million
- Implied Share Price: Approximately $8.91 per share (calculated from market value and share count)
Material Changes and Events
The primary material event reported is the resolution of a listing deficiency:
- Previous Non-Compliance: On July 30, 2026, the company received notice from Nasdaq that its bid price had closed below $1.00 per share for 30 consecutive business days (June 16, 2026, through July 29, 2026), violating Nasdaq Listing Rule 5550(a)(2).
- Compliance Period Denial: The company was initially denied a standard 180-day compliance period because it had executed a reverse stock split within the prior year.
- Resolution: On September 8, 2026, Nasdaq confirmed the company has regained compliance with the Minimum Bid Price Rule and the Rights/Warrants Rule (Rule 5560(a)).
- Hearing Cancellation: A scheduled hearing before the Nasdaq Hearings Panel for September 8, 2026, was cancelled following the confirmation of compliance.
Outlook, Risks, and Management Commentary
Management confirmed via a press release issued on September 9, 2026, that the company's securities will continue to be listed and traded on The Nasdaq Capital Market. The filing does not contain forward-looking guidance, risk factors, or commentary on operational outlook beyond the immediate resolution of the listing status.
Investor Verification Checklist
- Verify the current trading price of BIAF to ensure it remains above the $1.00 minimum bid price threshold.
- Review the attached press release (Exhibit 99.1) for any additional details on the company's capital structure or future plans.
- Monitor future filings for any new Nasdaq deficiency notices, given the company's recent history of low bid prices.
- Confirm the exact number of outstanding shares and warrant positions (BIAFW) in subsequent periodic reports (10-Q/10-K).